The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that"s 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
The global Microbiome Therapeutics market size was valued at US$ 132 million in 2023 and is forecast to a readjusted size of USD 1186 million by 2030 with a CAGR of 37.2% during review period.
The Application of Microbiome Therapeutics includes CDI, IBD, Orphan Drug, Immuno-oncology and Others, and the proportion of R&D Investmen for CDI is about 52%.
For Microbiome Therapeutics Pipeline Product, SER-109, ABI-H0731, ribaxamase, SYN-010 have the most investment in research, there are in Phase 3, PHASE 1b and Phase 2.
North American is the largest market, It occupy nearly 37% market share. Following North American, Europe is the second largest market with the consumption market share of 30%.
麻豆原创 competition is not intense. Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon and PureTech are the leading Developers in the industry, with about 60% market shares.
This report is a detailed and comprehensive analysis for global Microbiome Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Microbiome Therapeutics market size and forecasts, in consumption value ($ Million), 2019-2030
Global Microbiome Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Microbiome Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Microbiome Therapeutics market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Microbiome Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Microbiome Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma, Second Genome, AOBiome, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Microbiome Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segmentation
Microbiome Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Upper GIT
Lower GIT
麻豆原创 segment by Application
C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
麻豆原创 segment by players, this report covers
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Osel
Metabogen
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Microbiome Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Microbiome Therapeutics, with revenue, gross margin, and global market share of Microbiome Therapeutics from 2019 to 2024.
Chapter 3, the Microbiome Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Microbiome Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Microbiome Therapeutics.
Chapter 13, to describe Microbiome Therapeutics research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Microbiome Therapeutics by Type
1.3.1 Overview: Global Microbiome Therapeutics 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Microbiome Therapeutics Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Upper GIT
1.3.4 Lower GIT
1.4 Global Microbiome Therapeutics 麻豆原创 by Application
1.4.1 Overview: Global Microbiome Therapeutics 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 C. difficile Infection (CDI)
1.4.3 Inflammatory Bowel Disease (IBD)
1.4.4 Orphan Drug
1.4.5 Immuno-oncology
1.4.6 Others
1.5 Global Microbiome Therapeutics 麻豆原创 Size & Forecast
1.6 Global Microbiome Therapeutics 麻豆原创 Size and Forecast by Region
1.6.1 Global Microbiome Therapeutics 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Microbiome Therapeutics 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Microbiome Therapeutics 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Microbiome Therapeutics 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Microbiome Therapeutics 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Microbiome Therapeutics 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East & Africa Microbiome Therapeutics 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Seres Therapeutics
2.1.1 Seres Therapeutics Details
2.1.2 Seres Therapeutics Major Business
2.1.3 Seres Therapeutics Microbiome Therapeutics Product and Solutions
2.1.4 Seres Therapeutics Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Seres Therapeutics Recent Developments and Future Plans
2.2 Assembly Biosciences
2.2.1 Assembly Biosciences Details
2.2.2 Assembly Biosciences Major Business
2.2.3 Assembly Biosciences Microbiome Therapeutics Product and Solutions
2.2.4 Assembly Biosciences Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Assembly Biosciences Recent Developments and Future Plans
2.3 Synthetic Biologics
2.3.1 Synthetic Biologics Details
2.3.2 Synthetic Biologics Major Business
2.3.3 Synthetic Biologics Microbiome Therapeutics Product and Solutions
2.3.4 Synthetic Biologics Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Synthetic Biologics Recent Developments and Future Plans
2.4 Interxon
2.4.1 Interxon Details
2.4.2 Interxon Major Business
2.4.3 Interxon Microbiome Therapeutics Product and Solutions
2.4.4 Interxon Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Interxon Recent Developments and Future Plans
2.5 PureTech
2.5.1 PureTech Details
2.5.2 PureTech Major Business
2.5.3 PureTech Microbiome Therapeutics Product and Solutions
2.5.4 PureTech Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 PureTech Recent Developments and Future Plans
2.6 Synlogic
2.6.1 Synlogic Details
2.6.2 Synlogic Major Business
2.6.3 Synlogic Microbiome Therapeutics Product and Solutions
2.6.4 Synlogic Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Synlogic Recent Developments and Future Plans
2.7 Enterome BioScience
2.7.1 Enterome BioScience Details
2.7.2 Enterome BioScience Major Business
2.7.3 Enterome BioScience Microbiome Therapeutics Product and Solutions
2.7.4 Enterome BioScience Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Enterome BioScience Recent Developments and Future Plans
2.8 4D Pharma
2.8.1 4D Pharma Details
2.8.2 4D Pharma Major Business
2.8.3 4D Pharma Microbiome Therapeutics Product and Solutions
2.8.4 4D Pharma Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 4D Pharma Recent Developments and Future Plans
2.9 Second Genome
2.9.1 Second Genome Details
2.9.2 Second Genome Major Business
2.9.3 Second Genome Microbiome Therapeutics Product and Solutions
2.9.4 Second Genome Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Second Genome Recent Developments and Future Plans
2.10 AOBiome
2.10.1 AOBiome Details
2.10.2 AOBiome Major Business
2.10.3 AOBiome Microbiome Therapeutics Product and Solutions
2.10.4 AOBiome Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 AOBiome Recent Developments and Future Plans
2.11 C3 Jian
2.11.1 C3 Jian Details
2.11.2 C3 Jian Major Business
2.11.3 C3 Jian Microbiome Therapeutics Product and Solutions
2.11.4 C3 Jian Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 C3 Jian Recent Developments and Future Plans
2.12 Rebiotix
2.12.1 Rebiotix Details
2.12.2 Rebiotix Major Business
2.12.3 Rebiotix Microbiome Therapeutics Product and Solutions
2.12.4 Rebiotix Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 Rebiotix Recent Developments and Future Plans
2.13 MicroBiome Therapeutics LLC
2.13.1 MicroBiome Therapeutics LLC Details
2.13.2 MicroBiome Therapeutics LLC Major Business
2.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Product and Solutions
2.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.13.5 MicroBiome Therapeutics LLC Recent Developments and Future Plans
2.14 Metabiomics
2.14.1 Metabiomics Details
2.14.2 Metabiomics Major Business
2.14.3 Metabiomics Microbiome Therapeutics Product and Solutions
2.14.4 Metabiomics Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.14.5 Metabiomics Recent Developments and Future Plans
2.15 Ritter Pharmaceuticals
2.15.1 Ritter Pharmaceuticals Details
2.15.2 Ritter Pharmaceuticals Major Business
2.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Product and Solutions
2.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.15.5 Ritter Pharmaceuticals Recent Developments and Future Plans
2.16 Symberix
2.16.1 Symberix Details
2.16.2 Symberix Major Business
2.16.3 Symberix Microbiome Therapeutics Product and Solutions
2.16.4 Symberix Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.16.5 Symberix Recent Developments and Future Plans
2.17 OpenBiome
2.17.1 OpenBiome Details
2.17.2 OpenBiome Major Business
2.17.3 OpenBiome Microbiome Therapeutics Product and Solutions
2.17.4 OpenBiome Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.17.5 OpenBiome Recent Developments and Future Plans
2.18 Azitra
2.18.1 Azitra Details
2.18.2 Azitra Major Business
2.18.3 Azitra Microbiome Therapeutics Product and Solutions
2.18.4 Azitra Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.18.5 Azitra Recent Developments and Future Plans
2.19 Symbiotix Biotherapies
2.19.1 Symbiotix Biotherapies Details
2.19.2 Symbiotix Biotherapies Major Business
2.19.3 Symbiotix Biotherapies Microbiome Therapeutics Product and Solutions
2.19.4 Symbiotix Biotherapies Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.19.5 Symbiotix Biotherapies Recent Developments and Future Plans
2.20 Osel
2.20.1 Osel Details
2.20.2 Osel Major Business
2.20.3 Osel Microbiome Therapeutics Product and Solutions
2.20.4 Osel Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.20.5 Osel Recent Developments and Future Plans
2.21 Metabogen
2.21.1 Metabogen Details
2.21.2 Metabogen Major Business
2.21.3 Metabogen Microbiome Therapeutics Product and Solutions
2.21.4 Metabogen Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.21.5 Metabogen Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Microbiome Therapeutics Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Microbiome Therapeutics by Company Revenue
3.2.2 Top 3 Microbiome Therapeutics Players 麻豆原创 Share in 2023
3.2.3 Top 6 Microbiome Therapeutics Players 麻豆原创 Share in 2023
3.3 Microbiome Therapeutics 麻豆原创: Overall Company Footprint Analysis
3.3.1 Microbiome Therapeutics 麻豆原创: Region Footprint
3.3.2 Microbiome Therapeutics 麻豆原创: Company Product Type Footprint
3.3.3 Microbiome Therapeutics 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Microbiome Therapeutics Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Microbiome Therapeutics 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Microbiome Therapeutics Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Microbiome Therapeutics 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Microbiome Therapeutics Consumption Value by Type (2019-2030)
6.2 North America Microbiome Therapeutics 麻豆原创 Size by Application (2019-2030)
6.3 North America Microbiome Therapeutics 麻豆原创 Size by Country
6.3.1 North America Microbiome Therapeutics Consumption Value by Country (2019-2030)
6.3.2 United States Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Microbiome Therapeutics Consumption Value by Type (2019-2030)
7.2 Europe Microbiome Therapeutics Consumption Value by Application (2019-2030)
7.3 Europe Microbiome Therapeutics 麻豆原创 Size by Country
7.3.1 Europe Microbiome Therapeutics Consumption Value by Country (2019-2030)
7.3.2 Germany Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Microbiome Therapeutics Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Microbiome Therapeutics Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Microbiome Therapeutics 麻豆原创 Size by Region
8.3.1 Asia-Pacific Microbiome Therapeutics Consumption Value by Region (2019-2030)
8.3.2 China Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Microbiome Therapeutics Consumption Value by Type (2019-2030)
9.2 South America Microbiome Therapeutics Consumption Value by Application (2019-2030)
9.3 South America Microbiome Therapeutics 麻豆原创 Size by Country
9.3.1 South America Microbiome Therapeutics Consumption Value by Country (2019-2030)
9.3.2 Brazil Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Microbiome Therapeutics Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Microbiome Therapeutics Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Microbiome Therapeutics 麻豆原创 Size by Country
10.3.1 Middle East & Africa Microbiome Therapeutics Consumption Value by Country (2019-2030)
10.3.2 Turkey Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Microbiome Therapeutics 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Microbiome Therapeutics 麻豆原创 Drivers
11.2 Microbiome Therapeutics 麻豆原创 Restraints
11.3 Microbiome Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Microbiome Therapeutics Industry Chain
12.2 Microbiome Therapeutics Upstream Analysis
12.3 Microbiome Therapeutics Midstream Analysis
12.4 Microbiome Therapeutics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Osel
Metabogen
听
听
*If Applicable.
